Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv ...

23 September 2026 · By · Wire by Fusion42

Published

23 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at jnj.com →

◆ Verified

Fusion42 · 23 September 2026 · Fusion42 review

Johnson & Johnson announced Phase 3 MajesTEC-3 trial data showing TECVAYLI® plus DARZALEX FASPRO® significantly improves long-term survival and disease control in relapsed/refractory multiple myeloma compared to standard of care treatments.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now expect long-term survival rates in multiple myeloma patients to improve dramatically using TECVAYLI plus DARZALEX FASPRO. This opens a path to redesign treatment strategies and target durable disease control earlier in patient care.

◆ Coverage

1 source · 23 Sep 2026

◆ Related on Wire

◆ Topics

Biotechmultiple-myelomaclinical-trialsurvival-benefitoncologybiotech